The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Novartis (Inst); Orion (Inst); Redx Pharma (Inst); Roche (Inst); Starpharma (Inst); Taiho Pharmaceutical (Inst); Tarveda Therapeutics (Inst); UCB (Inst)
A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.
 
Debashis Sarker
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - AAA HealthCare; Bayer; Eisai; Ipsen; Novartis; Roche; Sirtex Medical; Surface Oncology; UCB (Inst)
Speakers' Bureau - AstraZeneca; Bayer; Eisai
Research Funding - UCB (Inst)
Travel, Accommodations, Expenses - MiNA Therapeutics
(OPTIONAL) Uncompensated Relationships - Medivir; MINA THERAPEUTICS
 
Udai Banerji
Employment - Institute of Cancer Research
Consulting or Advisory Role - Boehringer Ingelheim; Janssen; Phoenix Solutions
Research Funding - AstraZeneca (Inst); BTG (Inst); Chugai Pharma (Inst); Onyx (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Bayer; Sierra Oncology
 
Sarah Patricia Blagden
Honoraria - Nucana
Consulting or Advisory Role - Amphista Therapeutics; Ellipses Pharma; RApport Global; Theolytics; UCB
Research Funding - Astex Pharmaceuticals (Inst); Incyte (Inst); MSD (Inst); Nucana (Inst); Octimet (Inst); Redx Pharma (Inst); Roche (Inst); Sierra Oncology (Inst); Tesaro (Inst); UCB (Inst)
Patents, Royalties, Other Intellectual Property - RNA Guardian; RNA Guardian (I)
Travel, Accommodations, Expenses - Nucana; Tesaro
 
Natalie Cook
No Relationships to Disclose
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; Novartis; Octimet; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Marina Braun
Employment - UCB
Stock and Other Ownership Interests - UCB
 
Ann Cleverly
Employment - UCB
 
Nieves Diaz
Employment - UCB
Stock and Other Ownership Interests - UCB
 
Paul Jones
Employment - UCB
Stock and Other Ownership Interests - UCB
 
Ivan Matthews
Employment - UCB
Stock and Other Ownership Interests - GlaxoSmithKline; Lilly; UCB
 
Sophie Glatt
Employment - UCB
Stock and Other Ownership Interests - UCB
Patents, Royalties, Other Intellectual Property - UCB